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Summary.-The superiority of intra-arterial infusion with methotrexate (MTX)
over its systemic use in the treatment of head and neck tumours is still being
questioned. A model in the rat, suitable for intra-arterial administration of MTX
could be constructed. In this model 3 schedules have been investigated: (1) 7 days
continuous intra-arterial infusion with MTX; (2) the same schedule combined with
leucovorin (CF) 6-hourly intraperitoneally (i.p.) after Sullivan et al. (1959); (3) inter-
mittent administration of MTX 2 x 24 h intra-arterial infusion on Day 1 and 4,
while on Day 2, 3, 5, 6 and 7 the catheter is kept open by the continuous intra-arterial
infusion of saline. For all the three schedules intra-arterial MTX proved to be
superior to its systemic use.
INTRA-ARTERIAL infusion chemothe-
rapy has been carried out in the Antoni
van Leeuwenhoek Hospital (Amsterdam)
since 1964 as a planned adjuvant to
radiotherapy and/or surgery in far ad-
vanced head and neck cancer (Snow and
Sindram, 1973). Methotrexate was used
in the majority of cases. In recent years
the superioritv ofintra-arterial administra-
tion of cytotoxic drugs over their systemic
use has been questioned. Clinical evalua-
tion up till now has not been possible
due to the small number of patients
treated in each separate centre and also
to the lack of standardization of drug
schedules. It therefore seemed impor-
tant to get further information from
animal experimental work. The follow-
ing questions were posed: (1) Is it possible
to set up an animal model suitable for
continuous intra-arterial infusion of meth-
otrexate (MTX); (2) In this model, is
the anti-tumour effect of regional con-
tinuous intra-arterial infusion of MTX
superior to that ofthe continuous systemic
administration thereof; (3) Also, in an
intermittent dose schedule, is the anti-
tumour effect of regional intra-arterial
infusion of MTX superior to that of
systemic administration?
Until now there has been no success
in the development of such a model for
various reasons. In large animals such
as monkeys and dogs, no transplantable
tumours are available in inbred strains.
The same holds true for the rabbit.
Therefore only small animals like mice
and rats remain. These are easy to
handle and numerous transplantable tu-
mours are available in inbred strains.
However, these small animals present 2
major problems. First, the blood vessels
are very small, so that catheterization of
the analogous artery used in man-
external carotid artery is not practical.
Secondly, there is the problem of catheter
fixation, which has to be done in such
a way that the animal cannot break the
infusion system, yet still retains a certain
amount of mobility.
MATERIALS AND METHODS
In the following model for intra-arterial
infusion in the rat these problems have
been solved. Under general anaesthesia the
common carotid artery on one side is ligated
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FIG. 1. Schedule of blood supply after
ligation and cannulation of one common
carotid artery. The blocked bloodstream
has been taken over by the other side vie
the circulus Willisi.
and cannulated with a polyethylene catheter
No. 10 distally from the point of ligation
(Fig. 1). Blocking the bloodstream in this
way does not give any evident signs of
damage in the brain or head and neck
region.
The catheter is led subcutaneously to the
neck of the animal. A piece of thickwalled
silicon tubing, sutured subcutaneously to
the skin, gives a flexible connection between
the polyethylene catheter and a stainless
steel tube (gnaw-proof 1 mm). The
latter is attached to a swivel mounted over
the rat cage, which permits unlimited rota-
tion of the rat. An infusion pump (Brown
Unita 1) is connected to the fixed part of
the swivel by means of polyethylene tubing
No. 30. Infusion speed is 2-5 mlfh, infusion
being continued for 7 days, heparin, 10
i.u./24 h being added to the infusate.
In the case of intraperitoneal (i.p.)
injections, a second stainless steel tube has
been attached in the same way as the other
one. The polyethylene catheter from this
tube is led subcutaneously into the peri-
toneal cavity. A tobacco sack ligature in
the abdominal wall around the catheter
has proved to be an efficient means of
fixation of the catheter and to give pro-
tection from infection.
In the case of intermittent intra-arterial
MTX infusion on Day 1 and Day 4, the
catheter has been kept open by continuous
saline infusion on Day 2, 3, 5, 6 and 7.
The tumour we used is the transplantable
R-1 rhabdomyosarcoma, which arose in
1962 in the mandible of an irradiated rat.
This tumour was kindly supplied by Pro-
fessor G. W. Barendsen, Radiobiologic Insti-
tute, Rijswijk, Holland. A standardized
piece of tumour tissue is implanted in the
front margin ofeach ear in male (WAG x BN)
Fl hybrid rats of about 250 g body weight.
One of these tumours is infused locally with
MTX while the other tumour serves as a
control for the systemic effects. The ad-
vantage of this model is that we always
compare the anti-tumour effects of intra-
arterial and systemic MTX in the same
animal, and therefore always at the same
level oftoxicity. Tumour size was measured
in 3 dimensions and the product was used
as a parameter of tumour volume.
At the beginning of infusion these
volumes were between 200 and 400 mm3.
The tumour is non-sensitive to i.p. injections
of MTX (Franchi, Moretti and Garattini,
1970). This very resistant tumour has
been chosen because of the advantage that
volumes can always be measured accurately,
and a further consequence of this choice is
that cures cannot be expected.
RESULTS
First schedule: 7 days continuous intra-
arterial infusion of MTX
In preliminary experiments, the ani-
mals tolerated the saline infusion very
well and also some anti-tumour effects
of MTX were noticed. Some animals
died after a dose of 0 20 mg/kg/day
given continuously for 5 days. We de-
cided to extend the experiments to a
7-day period. The results of 0-14, 0-20
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FIG. 2.-Effect of 7 days' continuous intra-arterial infusion of MTX on tumour volume. Tumour
volume is expressed in relation to the tumour volume after saline infusion. The curves on the
left represent the effects of MTX alone; on the right MTX combined with CF i.p. 0 5 mg/kg
6-hourly. Each point represents the mean of at least 6 tumours. The bars indlicate the 95%
confidence limits of each point, the shaded areas that of the effects of saline infusion. The arrows
indicate the LD50 for each schedule (0-21 and 0-56 mg MTX/kg/24 h).
and 0-28 mg MTX/kg/day are given in
the left part of Fig. 2. There was some
saline effect and therefore all values are
expressed as a percentage of saline
controls, separately for infusion side and
systemic side. MTX causes a significant
anti-tumour effect at all dose levels on
the infused side, but only at the highest
dose level on the systemic side.
The calculation of the horizontal
distance between the 2 lines in the left
part of Fig. 2 results in a factor of 2-0,
indicating the dose ratio giving the same
decrease of tumour growth both on the
infused and the systemic side. From
these experimental data, it is quite
evident that in this model continuous
intra-arterial administration of MTX is
superior to its systemic administration.
Second schedule: 7 days continuous intra-
arterial infusion of MTX in combination
with citrovorumfactor (CF), 6-hourly i.p.
We have chosen a 6-hourly schedule
for CF as was used by Sullivan, Miller
24
and Sikes (1959). In preliminary studies,
hardly any protection could be derived
from CF in a ratio CF: MTX 1: 2.
Thus, we decided to continue with a high
and fixed dose of CF of 05 mgfkg every
6 h. The results of continuous intra-
arterial infusion of 035, 050, 070 and
100 mg MTX/kg/24 h in combination
with CF in this dose schedule are given
in the right part of Fig. 2.
On the infusion side, the 3 highest
doses give a decrease of tumour volume
significantly different from their saline
controls, while none do so on the systemic
side. Hence, it follows that for this
schedule also, intra-arterial infusion is
superior to systemic administration of
MTX.
At the LD50 dose level, the tumour
volume after MTX alone and MTX + CF
as a percentage of the saline control
values is 5900 and 71% respectively.
Hence this schedule of MTX + CF was
no better than that of MTX alone, and
probably even worse.
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It is remarkable that local toxicity
in both schedules, demonstrated as ery-
thema and necrosis of oral and nasal
mucosa, and of skin, has been observed
only once.
Third schedule: twice daily (x 2 in 24 h)
intra-arterial MTX infusion on Day 1
and 4. On the other days (2, 3, 5, 6
and 7) the catheter has been kept open by a
continuous intra-arterial saline infusion
In preliminary experiments, a dose
range of 0-28-0-80 mg MTX/kg/day re-
sulted in mortality and tumour volume
decrease. Further experiments have been
carried out at a dose level of 0*50 mg
MTX/kg/day for a total of twice this
dose, 1.00 mg MTX/kg in 1 week of
infusion. The anti-tumour effect after
this dose (9 animals), relative to the
saline controls, was a mean tumour
volume decrease to 51% on the infusion
side and no significant difference on the
systemic side. Hence, for this inter-
mittent MTX schedule as well, the anti-
tumour effect of regional intra-arterial
MTX is superior to its systemic adminis-
tration. There was no mortality whereas
a similar anti-tumour effect with con-
tinuous MTX was observed only at a
dose of about the LD50 level. Hence, the
intermittent MTX schedule is probably
better, and certainly not worse than the
continuous schedules for MTX alone and
MTX + CF.
DISCUSSION
For all schedules, the anti-tumour
effect on the infusion side was always
superior to that on the systemic side.
Moreover, the intermittent schedule is
probably better than the 2 continuous
schedules.
In clinical studies, intra-arterial in-
fusion of MTX has always been applied
in a continuous schedule with a mean
remission rate of 53% reported in recent
publications (Bilder and Hornova, 1970;
Couture and Deschenes, 1972; Desprez et
al., 1972; Freckmann, 1972; Snow and
Sindram, 1973).
Systemically, however, MTX has been
applied in head and neck cancer both as
monthly 5-day courses, with a mean
remission rate of 28% (Huseby and
Downing, 1962; Papac, 1963; Hellman,
Lanotti and Bertino, 1964; Andrews and
Wilson, 1967; Sullivan et al., 1967) and
intermittently as intravenous injections,
weekly or every 4th day, or 24-48 h
intravenous infusions followed by leuco-
vorin rescue, with a mean remission rate
of respectively 42% and 43% (Papac,
Lefkowitz and Bertino, 1967; Lane et al.,
1968; Leone, Albala and Rege, 1968;
Healy, Moriarty and Maddock, 1971;
Priestman, 1973; Lefkowitz, Papac and
Bertino, 1967; Mitchell et al., 1968;
Capizzi et al., 1970; Levitt et al., 1972).
The results from the experiments and
the data from the mentioned publications
TABLE.-" Overall " Results of Intra-arterial and Systemic Administration of MTX
Alone or in Combination with CF, in the Head and Neck Region
Schedule
No. of
patients
evaluated
Monthly courses 5-10 89
days i.v. or by os
Fractionated i.v. injec- 174
tions
Fractionated i.v. infusions 83
followedbyCF "rescue"
Continuous intra-arterial, 478
early large series 346
Continuous intra-
arterial
Toxicity
No. (%) of patients, A
I
with a remission of Of bone
,________ marrow Local Mortality
> 50% 75-100% (%) (0%) (%)
28 0
(total)
(ENT
only)
724 (total)
> 445 (ENT
only)
2
Mortality
caused by
other
complications
(%)
42 9 48 36 3-4
43 8*3 24 21 4.8
10 13-5 3 1 4.3
55 22
53 23
6-5 4.5 0 1*1
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(Table) suggest that for clinical applica-
tion the best results in selected patients
might be obtained by combining both
principles: intra-arterial infusion and in-
termittent administration, that is, frac-
tionated intra-arterial infusions or injec-
tions.
A second suggestion might be derived
from the experimental results and data
in the literature: In our model the
anti-tumour effect attained with MTX+
CF i.p. 6-hourly (after Sullivan's schedule
for head and neck cancer) was no better
than MTX alone and even probably
worse. It might be that this 6-hourly
schedule is not the best schedule for the
antidote. There are some arguments to
support this: in experiments with leuk-
aemia L 1210 (Goldin et al., 1955, 1966)
the therapeutic effect of simultaneous
MTX + CF was worse than that of MTX
alone. However, when CF was adminis-
trated 12-24 h after MTX, the combina-
tion proved to be better than MTX alone.
The results of Bagshawe (1969) agree with
this. He obtained better results if CF,
in combination with continuous MTX
infusion, was given only twice daily
than when it was given 3 or 4 times daily.
AITX + 1.2-hourly i.m. CF was at least as
effective as MTX alone, but less toxic.
The above suggests that the effectiveness
of MTX + CF in treatment of head and
neck cancer might be increased by
changing the schedule for the antidote
CF from 6-hourly into 12-hourly i.m.
For all schedules, the anti-tumour
effect on the infusion side was superior
to that on the systemic side. Moreover,
the intermittent schedule is probably
better than the 2 continuous schedules.
Of the 2 continuous schedules, the com-
bination MTX and CF was no better
than MTX alone and probably even
worse.
These results and data in the literature
suggest that for clinical application: (1)
the best results in selected patients
might be obtained by combining both
principles: regional intra-arterial infusion
and intermittent administration, hence
with fractionated intra-arterial infusions
or injections; (2) the effectiveness of
MTX + CF in the treatment of head
and neck cancer might be increased by
changing the schedule for the antidote
CF from 6-hourly to 12-hourly i.m.
REFERENCES
ANDREWS, N. C. & WILSON, W. L. (1967) Phase II
Study ofMethotrexate (nsc. 740) in Solid Tumours.
Cancer Chemother. Rep., 51, 471.
BAGSHAWE, K. D. (1969) Choriocarcinoma. Ed. E.
Arnold. London.
BILDER, J. & HORNOVA, J. (1970) Analysis of the
Results ofRegional Chemotherapy for Carcinomas
of the Orofacial Region. Neoplasma, 17, 85.
CAPIZZI, R. L., DECONTI, R. C., MARCH, J. C. &
BERTINO, J. R. (1970) Methotrexate Therapy of
Head ancd Neck Cancer: Improvement in Thera-
peutic Index by the Use ofLeucovorin " Rescue
Cancer Res., 30, 1782.
COUT-RE, J. & DESCHENES, L. (1972) Intia-arterial
Infusion An Adjuvant to the Treatment of
Oral Carcinoma. Cancer, N.Y., 29, 1632.
DESPREZ, J. D., KIEHN, C. L., SCIOTTO, C. &
RAMIREZ-GONZALES, M. (1972) Response of
Oral Carcinoma to Preoperative Methotrexate
with Citrovorum Factor in Patients with Lung
Cancer. Cancer, N.Y., 30, 33.
FRANCHI, G., MORETTI, L. & GARTTINI, S. (1970)
Experimental Chemotherapy of a Transplantable
Rhabdomyosarcoma in the Rat. Eur. J. Canicer,
6, 441.
FRECKMANN, H. A. (1972) Results in 169 Patients
with Cancer of the Head and Neck Treated by
Intra-arterial Infusion Therapy. Am. J. Surg.,
124, 501.
GOLDIN, A., VENDITTI, J. A., HUMPHREYS, S. R.,
DENNIS, D. & MANTEL, N. (1955) Stucdies on the
AManagement of Mouse Leukemia (L 1210) with
Antagonists of Folic Acid. Cancer Res., 15, 742.
GOLDIN, A., VENDITTI, J. M., KLINE, I. & MANTEL,
N. (1966) Eradication of Leukaemic Cells (L 1210)
by Methotrexate and Methotrexate plus Citro-
vorum Factor. Nature, Lond., 212, 1548.
HEALY, J. B., MORIARTY, AM. J. & MADDOCK, P. G.
(1971) Treatment of Advanced Cancer of Head
an(d Neck by Large Doses of Methotrexate. J.
Jr. med. Ass., 64, 376.
HELLMAN, S., LANOTTI, A. T. & BERTINO, J. R.
(1964) Determinations of the Levels of Serum
Folate in Patients with Carcinoma of the Head
and Neck Tireated with Methotrexate. Cancer
Res., 24, 105.
HUSEBY, R. A. & DOwNNING, V. (1962) The Use
of Methotrexate Orally in Treatment of Squamous
Cancers of the Headl an(d Neck. Cancer Chemo-
ther. Rep., 16, 511.
LANE, M., MIOORE, J. E., LEVIN, H. & SMITH,
F. E. (1968) MIethotrexate Therapy for Squamous
Cell Carcinomas of the Head and Neck. J. Am.
me(l. Ass., 204, 56.
LEFKOW1TZ, E., PAPAC, R. J. & BERTINO, J. R.
(1967) Head and Neck Cancer. III. Toxicity of
24-hour Infusions of MTethotrexate (NSC-740)354 P. J. SINDRAM, G. B. SNOW AND L. M. VAN PUTTEN
and Protection by Leucovorin (NSC-3590) in
Patients with Epidermoid Carcinomas. Cancer
Chemother. Rep., 51, 305.
LEONE, L. A., ALBALA, M. M. & REGE, V. B.
(1968) Treatment of Carcinoma of the Head and
Neck with Intravenous Methotrexate. Cancer,
N.Y., 21, 828.
LEVITT, M., MOSHER, M. B., DECONTI, R. C.,
FARBER, L. R., MARSH, J. C., MITCHELL, M. S.,
PAPAC, R. J., THOMAS, E. D. & BERTINO, J. R.
.(1972) High Dose Methotrexate (MTX) vs.
Methotrexate-Leucovorin (N5-formyltetrahydro-
folate) in Epidermoid Carcinomas of the Head
and Neck. Proc. Am. Ass. Cancer Res., 13,
20.
MITCHELL, M. S., WAWRO, N. W., DECONTI, R. C.,
KAPLAN, S. R., PAPAC, R. & BERTINO, J. R.
(1968) Effectiveness of High-dose Infusions of
Methotrexate Followed by Leucovorin in Car-
cinoma of the Head and Neck. Cancer Res.,
28, 1089.
PAPAC, R. J., JACOBS, E. M., FOYE, L. V. & DONO-
HUE, D. M. (1963) Systemic Therapy with
Amethopterin in Squamous Carcinoma of the
Head and Neck. Cancer Chemother. Rep., 32,
47.
PAPAC, R., LEFKOWITZ, E. & BERTINO, J. R.
(1967) Methotrexate (NSC 740) in Squamous Cell
Carcinoma of the Head and Neck. II. Inter-
mittent Intravenous Therapy. Cancer Chemo-
ther. Rep., 51, 69.
PRIESTMAN, T. J. (1973) Results in Fifty Cases of
Advanced Squamous Cell Carcinoma of the Head
and Neck Treated by Intravenous Chemotherapy.
Br. J. Cancer, 27, 400.
SNOW, G. B. & SINDRAM, P. J. (1973) Intra-arterial
Infusion Chemotherapy in Head and Neck
Cancer, a Clinical and Experimental Study.
Archs chir. Nedrl., 30, 363.
SULLIVAN, R. D., MILLER, E. & SIKES, M. P.
(1959) Anti-metabolite-combination Cancer Che-
motherapy (Effects ofIntra-arterial Methotrexate,
Intra-muscular Citrovorum Factor Therapy in
Human Cancers). Cancer, N. Y., 12, 1248.
SULLIVAN, R. D., MILLER, E., ZUREK, W. Z., OBER-
FIELD, R. A. & OJIMA, Y. (1967) Re-evaluation
of Methotrexate as an Anticancer Drug. Surg-
ery Gynec. Obstet., 125, 819.